The role of screening mammography in the era of modern breast cancer treatment

Climacteric

Volumn 21, Issue 3, 2018, Pages 204-208

  Miller, A B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; mammography; screening; treatment

Indexed keywords

BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CANCER SCREENING; EARLY CANCER DIAGNOSIS; HUMAN; MAMMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; ADULT; BREAST TUMOR; DIAGNOSTIC IMAGING; FEMALE; MASS SCREENING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85046769613     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697137.2017.1392503     Document Type: Review

References (49)

1. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA., Twenty five year follow-up for breast cancer incidence and mortality of the Canadian national breast screening study: randomised screening trial. BMJ 2014;348:g366
2. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW., Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol 2015;16:1123–32
3. Miller AB., Conundrums in screening for cancer. Mini review. Int J Cancer 2010;126:1039–46
4. Prorok PC, Chamberlain J, Day NE, Hakama M, Miller AB., UICC workshop on the evaluation of screening programmes for cancer. Int J Cancer 1984;34:1–4
5. Miller AB. Fundamental issues in screening for cancer. In: Schottenfeld D, Fraumeni JF, Jr, eds. Cancer Epidemiology and Prevention. 2nd ed. New York, Oxford: Oxford University Press; 1996:1433–52
6. Shapiro S, Venet W, Strax P, Venet L, Roeser R., Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69:349–55
7. Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 1999;353:1903–8
8. Tabar L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260:658–63
9. Tabar L, Chen HH, Duffy SW, Kruesmo UB., Primary and adjuvant therapy, prognostic factors and survival in 1053 breast cancers diagnosed in a trial of mammography screening. Jpn J Clin Oncol 1999;29:608–16
10. Baines CJ, To T, Miller AB., Revised estimates of overdiagnosis from the Canadian national breast screening study. Prev Med 2016;90:66–71
11. EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen 2012;19(Suppl 1):5–13
12. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst 2014;106:dju261
13. Johns LE, Coleman DA, Swerdlow AJ, Moss SM., Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study. Br J Cancer 2017;116:246–52
14. Miller AB., Comment on ‘Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study'. Br J Cancer 2017;117:e2
15. Jatoi I, Miller AB., Why is breast cancer mortality declining? Lancet Oncol 2003;4:251–4
16. Burton RC, Bell RJ, Thiagarajah G, Stevenson C., Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. Breast Cancer Res Treat 2012;131:949–55
17. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784–92
18. Miller BA, Feuer EJ, Hankey BF., The increasing incidence of breast cancer since 1982: relevance of early detection. Cancer Causes Control 1991;2:67–74
19. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–4
20. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
21. Morrell S, Taylor R, Roder D, Robson B, Gregory M, Craig K., Mammography service screening and breast cancer mortality in New Zealand: a national cohort study 1999–2011. Br J Cancer 2017;116:828–39
22. Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014;15:e234–42
23. Elshof LE, Tryonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ–the LORD study. Eur J Cancer 2015;51:1497–510
24. Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 2015;51:2296–303
25. Youngwirth LM, Boughey JC, Hwang ES., Surgery versus monitoring and endocrine therapy for low-risk DCIS: the COMET Trial. Bull Am Coll Surg 2017;102:62–3
26. Klotz L., Active surveillance: the Canadian experience with an “inclusive approach”. J Natl Cancer Inst Monogr 2012;2012:234–41
27. Birnbaum J, Gadi VK, Markowitz E, Etzioni R., The effect of treatment advances on the mortality results of breast cancer screening trials: a microsimulation model. Ann Intern Med 2016;164:236–43
28. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M., The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013;108:2205–40
29. IARC Handbook of Cancer Prevention, Volume 15. Breast Cancer Screening. Lyon: International Agency for Research on Cancer, 2016
30. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S., Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 1992;24:11–16
31. Baines CJ, McFarlane DV, Wall C., Audit procedures in the national breast screening study: mammography interpretation. Can Assoc Radiol J 1986;37:256–60
32. Baines CJ, McFarlane DV, Miller AB., The role of the reference radiologist. Estimates of inter-observer agreement and potential delay in cancer detection in the national breast screening study. Invest Radiol 1990;25:971–6
33. Baines CJ, Miller AB, Kopans DB, et al. Canadian national breast screening study: assessment of technical quality of external review. Am J Roentgenol 1990;155:743–74
34. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993;85:1644–56
35. Miller AB., Editorial: digital mammography. J Natl Cancer Inst 2014;106:dju125
36. Boyd NF, Jong RA, Yaffe MJ, Tritchler D, Lockwood G, Zylak CJA., critical appraisal of the national breast cancer screening study. Radiology 1993;189:661–3
37. Kopans DB, Feig SA. The Canadian national breast Screening Study: a critical review. Am J Roentgenol 1993;161:755–60
38. Tarone RE., The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian national breast screening study. Cancer 1995;75:997–1003
39. Miller AB, Baines CJ, To T, Wall C., Canadian national breast screening study. 1. Breast cancer detection and death rates among women age 40–49 years. Can Med Assoc J 1992;147:1459–76
40. Miller AB, Baines CJ, To T, Wall C., Canadian national breast screening study. 2. Breast cancer detection and death rates among women age 50-59 years. Can Med Assoc J 1992;147:1477–88
41. Cox B., Variation in the effectiveness of breast screening by year of follow-up. Monogr Natl Cancer Inst 1997;22:69–72
42. Kerr M. A case-control study of treatment adequacy and mortality from breast cancer for women age 40-49 years at entry into the national breast screening study. Masters Thesis. Toronto: University of Toronto; 1991
43. Miller AB, To T, Baines CJ, Wall C., The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 2002;137:305–12
44. Retsky M, Demicheli R, Hrushesky W., Breast cancer screening for women aged 40–49 years: screening may not be the benign process usually thought. J Natl Cancer Inst 2001;93:1572
45. Mittra I, Mishra GA, Singh S, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010;126:976–84
46. Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 2011;103:1476–80
47. Miller AB, Baines CJ, Turnbull C., The role of the nurse-examiner in the National Breast Screening Study. Can J Public Health 1991;82:162–7
48. World Health Organization. Guide to Cancer Early Diagnosis. Geneva: World Health Organization; 2017
49. Gadgil A, Sauvaget C, Roy N, et al. Cancer early detection program based on awareness and clinical breast examination: interim results from an urban community in Mumbai, India. Breast 2017;31:85–9